Development and Validation of a Decision-Making Stratification Algorithm to Optimize the Use of Rapid Diagnostic Testing for Patients with Staphylococcus Bacteremia

Table 1

Patients who met inclusion criteria for rapid diagnostic testing.

Age	Gender	Empiric therapy	Isolated microorganism	Plan made	Time to optimal antibiotic therapy (hours) using culture based method	Expected time avoided (hours) to optimal antibiotic therapy using the molecular diagnostic test
61	F	Vancomycin	MSSA	Changed to nafcillin	78	74
68	M	Vancomycin	CoNS	Vancomycin discontinued	44	42
32	F	Vancomycin and levofloxacin	CoNS	Discharged from ED	n/a
78	F	Vancomycin	CoNS	Vancomycin discontinued	30	28
74	F	Vancomycin and doxycycline	CoNS	Vancomycin discontinued and patient discharged	49	47
49	M	Vancomycin	CoNS	Discharged from ED	n/a
80	F	Vancomycin and ceftriaxone	Micrococcus	Vancomycin discontinued	28	26
85	F	Vancomycin and piperacillin/tazobactam	CoNS	Vancomycin discontinued	22	20
29	M	Vancomycin	CoNS	Vancomycin discontinued	31	29

F = female, M = male, MSSA = methicillin-susceptible Staphylococcus aureus, CoNS = coagulase-negative staphylococci, and ED = emergency department. Patients were called to return for emergency department evaluation, to assess clinical status and repeat blood cultures.